Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ReShape Weightloss Inc.RSLS · Entity 137993 | Chief Financial Officer | June 15, 2021 | June 17, 2021 |
| Vyome Holdings, IncRSLS · Entity 1824 | Chief Financial Officer | November 30, 2023 | August 13, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ReShape Weightloss Inc.
Report date June 15, 2021 · Filed June 17, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.001 par value per shareSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2021-06-15 transaction · row 1
1 source rowRow 1 · 2021-06-15 · Disposition to issuer · Disposed 4,635 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger by and among the issuer, Obalon Therapeutics, Inc. ("Obalon"), and Optimus Merger Sub, Inc., which became effective on June 15, 2021, in exchange for 2,613 shares of common stock of Obalon having a market value of $3.05 per share at the effective time of the merger. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to the Agreement and Plan of Merger by and among the issuer, Obalon Therapeutics, Inc. ("Obalon"), and Optimus Merger Sub, Inc., which became effective on June 15, 2021, in exchange for 2,613 shares of common stock of Obalon having a market value of $3.05 per share at the effective time of the merger.
Vyome Holdings, Inc
Report date November 30, 2023 · Filed August 13, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.001 par value per shareSEC Table I · non-derivative | Direct | 22,777 |
Ending reported balance
After 2024-05-31 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2023-11-30 · Sale · Disposed 39 · Balance 22,910 F1: On July 22, 2021, Mr. Stankovich was awarded an aggregate of 7,455 restricted stock units, all of which, including the unvested portion, were reported on a Form 4 filed on September 17, 2021. The shares reported under this Form 4 as being disposed of were sold to cover taxes in connection with the vesting of a portion of those previously reported restricted stock units. Row 2 · 2023-12-31 · Sale · Disposed 42 · Balance 22,868 F1: On July 22, 2021, Mr. Stankovich was awarded an aggregate of 7,455 restricted stock units, all of which, including the unvested portion, were reported on a Form 4 filed on September 17, 2021. The shares reported under this Form 4 as being disposed of were sold to cover taxes in connection with the vesting of a portion of those previously reported restricted stock units. Row 3 · 2024-02-29 · Sale · Disposed 43 · Balance 22,825 F1: On July 22, 2021, Mr. Stankovich was awarded an aggregate of 7,455 restricted stock units, all of which, including the unvested portion, were reported on a Form 4 filed on September 17, 2021. The shares reported under this Form 4 as being disposed of were sold to cover taxes in connection with the vesting of a portion of those previously reported restricted stock units. Row 4 · 2024-05-31 · Sale · Disposed 48 · Balance 22,777 F1: On July 22, 2021, Mr. Stankovich was awarded an aggregate of 7,455 restricted stock units, all of which, including the unvested portion, were reported on a Form 4 filed on September 17, 2021. The shares reported under this Form 4 as being disposed of were sold to cover taxes in connection with the vesting of a portion of those previously reported restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: On July 22, 2021, Mr. Stankovich was awarded an aggregate of 7,455 restricted stock units, all of which, including the unvested portion, were reported on a Form 4 filed on September 17, 2021. The shares reported under this Form 4 as being disposed of were sold to cover taxes in connection with the vesting of a portion of those previously reported restricted stock units.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 22, 2021 Filed Sep 17, 2021 18:51 UTC | Vyome Holdings, Inc RSLS · Entity 1824 | GrantCommon Stock, $0.001 par value per share | 90,362 | $0.00 | $0.00 |
DisclosureSEC source: 0001790300-21-000010 · primary_doc.xml · nonDerivative · entry 2 STANKOVICH THOMAS · CIK 0001181166 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 406,357 F2 · shares: These shares will vest and be issued monthly over 36 months beginning on July 22, 2021 pursuant to a restricted stock unit granted under the ReShape Lifesciences Inc. Second Amended and Restated 2003 Stock Incentive Plan. Read SEC document |
| July 22, 2021 Filed Sep 17, 2021 18:51 UTC | Vyome Holdings, Inc RSLS · Entity 1824 | GrantCommon Stock, $0.001 par value per share | 282,382 | $0.00 | $0.00 |
DisclosureSEC source: 0001790300-21-000010 · primary_doc.xml · nonDerivative · entry 1 STANKOVICH THOMAS · CIK 0001181166 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 315,995 F1 · shares: These shares will vest and be issued with respect to 123,542 shares on July 22, 2021 and the remaining shares vesting monthly thereafter for 36 months pursuant to a restricted stock unit granted under the ReShape Lifesciences Inc. Second Amended and Restated 2003 Stock Incentive Plan. Read SEC document |
| June 15, 2021 Filed Jun 17, 2021 16:06 UTC | ReShape Weightloss Inc. RSLS · Entity 137993 | Disposition to issuerCommon Stock, $0.001 par value per share | 4,635 | $3.05 | $14,136.75 |
DisclosureSEC source: 0001235802-21-000055 · primary_doc.xml · nonDerivative · entry 1 STANKOVICH THOMAS · CIK 0001181166 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Disposed of pursuant to the Agreement and Plan of Merger by and among the issuer, Obalon Therapeutics, Inc. ("Obalon"), and Optimus Merger Sub, Inc., which became effective on June 15, 2021, in exchange for 2,613 shares of common stock of Obalon having a market value of $3.05 per share at the effective time of the merger. F1 · shares: Disposed of pursuant to the Agreement and Plan of Merger by and among the issuer, Obalon Therapeutics, Inc. ("Obalon"), and Optimus Merger Sub, Inc., which became effective on June 15, 2021, in exchange for 2,613 shares of common stock of Obalon having a market value of $3.05 per share at the effective time of the merger. F1 · price: Disposed of pursuant to the Agreement and Plan of Merger by and among the issuer, Obalon Therapeutics, Inc. ("Obalon"), and Optimus Merger Sub, Inc., which became effective on June 15, 2021, in exchange for 2,613 shares of common stock of Obalon having a market value of $3.05 per share at the effective time of the merger. Read SEC document |
| September 16, 2020 Filed Sep 17, 2020 18:08 UTC | ReShape Weightloss Inc. RSLS · Entity 137993 | PurchaseCommon Stock | 530 | $3.00 | $1,590.00 |
DisclosureSEC source: 0001104659-20-106184 · a4.xml · nonDerivative · entry 1 STANKOVICH THOMAS · CIK 0001181166 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,635 Read SEC document |
| August 19, 2020 Filed Aug 20, 2020 16:18 UTC | ReShape Weightloss Inc. RSLS · Entity 137993 | PurchaseCommon Stock | 4,105 | $3.00 | $12,315.00 |
DisclosureSEC source: 0001790300-20-000001 · primary_doc.xml · nonDerivative · entry 1 STANKOVICH THOMAS · CIK 0001181166 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,105 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.